SCHEMBL17045933

SCHEMBL17045933

COc1ccc(CSCCCCC(=O)NO)cc1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 9/20 0.59
HDAC8 Q9BY41 6/20 0.59
HDAC2 Q92769 6/20 0.59
HDAC6 Q9UBN7 5/20 0.59
HDAC3 O15379 4/20 0.59
HDAC10 Q969S8 4/20 0.59
HDAC4 P56524 3/20 0.59
HDAC7 Q8WUI4 3/20 0.59
HDAC11 Q96DB2 3/20 0.59
HDAC9 Q9UKV0 3/20 0.59
HDAC5 Q9UQL6 3/20 0.59
ALDH1A1 P00352 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
PKM P14618 1/20 0.56
MMP1 P03956 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17045908 0.86 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2PKML3MBTL1
SCHEMBL530979 0.82 PDE4B (0.54) ALDH1A1SMN1; SMN2PKM
SCHEMBL17045851 0.81 HDAC1 (0.61) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL11264089 0.81 GAA (0.64) ALDH1A1SMN1; SMN2PKMMMP1
SCHEMBL29016749 0.81 HDAC1 (0.68) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL17056731 0.80 RAB9A (0.56) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL31734071 0.80 RAB9A (0.56) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL9663885 0.80 HDAC1 (0.70) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL31734082 0.80 HDAC1 (0.65) HDAC1HDAC8HDAC2HDAC6HDAC3
SCHEMBL17045917 0.80 HDAC1 (0.65) HDAC1HDAC8HDAC2HDAC6HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12478594-B2 Methods of treatment of kidney injury associated with infection or trauma University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-11-25 US claimed
US-12478594-B2 Methods of treatment of kidney injury associated with infection or trauma University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-11-25 US disclosed
US-20220226266-A1 Methods of Treatment of Kidney Injury Associated with Infection or Trauma NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-07-21 US disclosed
WO-2020240524-A2 METHODS OF TREATMENT OF KIDNEY INJURY ASSOCIATED WITH INFECTION OR TRAUMA UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2020-12-03 WO disclosed
US-10233201-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburg—Of the Commonwealth System of Higher Education (US) 2019-03-19 US disclosed
US-20170320898-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2017-11-09 US disclosed
US-9670236-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2017-06-06 US disclosed
US-9670236-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2017-06-06 US disclosed
US-20150246939-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2015-09-03 US disclosed
US-20150246939-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2015-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10233201-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury HDAC1, HDAC9, HDAC11 HDAC1 1/4885HDAC8 7/4885HDAC2 6/4885
US-20220226266-A1 Methods of Treatment of Kidney Injury Associated with Infection or Trauma MMP8, PLAU, KLKB1 HDAC1 1068/4885HDAC8 1136/4885HDAC2 1113/4885
US-20150246939-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury HDAC1, HDAC9, HDAC11 HDAC1 1/4885HDAC8 7/4885HDAC2 6/4885
US-12478594-B2 Methods of treatment of kidney injury associated with infection or trauma HDAC1, HDAC2, HDAC4 HDAC1 1/4885HDAC8 8/4885HDAC2 2/4885
US-20170320898-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury HDAC1, HDAC9, HDAC11 HDAC1 1/4885HDAC8 7/4885HDAC2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.